Phase 4 N=600 Premature Discontinuation of Contraceptive Implants
Contraception Behavior
Primary: Number of Participants With Implant Continuation — 219; 225 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=59 Immediate vs. Delayed Postpartum Etonogestrel Implant
Continuation Rate of Contraceptive Implant
Primary: Continuation Rate — 20; 18 participants
N/A N=321 A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods
Contraception
Primary: Continuation Rates — 82; 78; 83 participants
Phase 4 N=96 Postpartum Etonogestrel Implant for Adolescents
Adolescence · Contraception · Postpartum
Primary: Continuation at 1 Year — 21; 30 participants
Phase 4 N=69 Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant
Complications; Contraceptive · Female Lactation
Primary: Time to Lactogenesis Stage II — 64.3; 65.2 hours — p=<0.05
Phase 3 N=81 Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents
Contraceptive Usage
Primary: Number of Participants With Contraceptive Implant Continuation at Six Months Postpartum — 15; 7 Participants
N/A N=155 Immediate Postpartum Contraceptive Implant Placement and Breastfeeding Success in Women at Risk for Low Milk Supply: A Non-inferiority Trial
Contraception · Breastfeeding · Postpartum Contraception
Primary: Number of Participants Breastfeeding at 6 Months — 6; 4; 6 Participants
Phase 3 N=95 Labor and Delivery Implant Insertion: A Randomized Controlled Trial
Postpartum Contraception · Family Planning
Primary: Time to Lactogenesis Stage II [Questionnaire] — 65; 67.5 hours
Early Phase 1 N=40 Ovarian Function With ENG Implant and UPA Use
Contraception
Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants
N/A N=46 Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women
Breastfeeding · Contraception
Primary: Etonogestrel-releasing Contraceptive Subdermal Implant Inserted During the Immediate Puerperium Effects on the Hemostatic System of Healthy Women Over a Period of Twelve…
Phase 4 N=109 Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
Bleeding · Implants · Breakthrough Bleeding
Primary: Total Number of Consecutive Bleeding-free Days in First 30 Days From Day 1 of First Treatment (TX1) — 18.5; 8.7 days
Phase 4 N=5 Shoulder Contraceptive Implant Study
Contraception
Primary: Pharmacokinetics in the Form of Serum Etonogestrel Concentrations — 511.7; 136.6 pg/mL
Phase 4 N=24 Rifampin and the Contraceptive Implant
Contraception · Tuberculosis
Primary: Serum Etonogestrel Concentrations — 164.0; 47.8 pg/mL
Phase 2 N=72 Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women
HIV/AIDS · Contraception
Primary: Proportion of Participants That Ovulate During Month 3 — 11; 0 Participants — p=<.001
N/A N=208 Home-based Delivery of the Contraceptive Implant in Postpartum Guatemalan Women
Postpartum
Primary: Number of Participants With Implant Use at Three Months — 28; 2 Participants
N/A N=293 Same Day Oral EC and Implant Initiation
Contraception
Primary: Pregnancy Rate at One-month — 1.96 percentage of participants
Phase 1 N=48 The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users
Migraine · Migraine;Menstrual · Contraception
Primary: Serum Etonogestrel Concentrations — 142.0; 126.0; 119.0; 105.0 pg/mL
Phase 2 N=32 Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study
Uterine Hemorrhage · Contraception
Primary: Cessation of Vaginal Bleeding — 37.5; 87.5 percentage of participants
N/A N=100 The Impact of Contraception on Postpartum Weight Loss
Weight
Primary: Weight — 3.2; 6.8; 7.0 percent weight lost — p=<0.05
Phase 3 N=301 A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)
Contraception
Primary: Percentage of Applicator Users Who Were Very Satisfied and Satisfied- User Satisfaction Questionnaire for Domain: Design & Technical Aspects — 99.1 Percentage of…
N/A N=29 Mirena Intrauterine System Timing of Insertion: A Randomized Controlled Trial
Postpartum Period
Primary: Mirena in Place — 10; 3 participants
Phase 3 N=65 Intervention to End Recurrent Unscheduled Bleeding Trial
Contraception · Bleeding
Primary: Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries — 7; 12 days — p=0.002
N/A N=148 Nexplanon Application Post-Abortion (NAPA)
Contraception · Abortion, Therapeutic
Primary: Intention-to-treat Analysis of Etonogestrel Implant Use — 40; 19; 3; 3 Participants
Phase 4 N=150 Breastfeeding Etonogestrel Implant Study
Contraception
Primary: Number of Participants With Continuation of Breastfeeding at 8 Weeks Postpartum — 54; 45; 48; 43 Participants
N/A N=120 Insertion of an Intrauterine Device (IUD) After Medical Abortion
Intrauterine Device Expulsion · Medical Abortion · Induced Abortion
Primary: Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion. — 4 percentage of participants
Phase 4 N=20 Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study
Contraception
Primary: Number of Participants Evaluating ENG as Acceptable: Acceptability (Measurement: Questionnaire) — 9; 8 Participants
N/A N=88 Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant
Etonogestrel Contraceptive Implant, Bothersome Bleeding
Primary: Impact of Aygestin (and Dose of Aygestin) on the Management of Bothersome Bleeding Associated With the Etonogestrel Contraceptive Implant — 2.73; 2.77; 2.76; 2.27 units…
N/A N=123 Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
Contraception
Primary: IUD Expulsion Rate — 20; 7 Participants
N/A N=102 Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device (IUD) After Vaginal Delivery
Contraception
Primary: IUD Usage Rate at 6 Months — 43; 39 participants
Phase 4 N=50 LNG-IUS at 2 Weeks Postpartum
Contraception · Malposition of Intrauterine Contraceptive Device
Primary: Number of Participants Who Would Recommend the LNG-IUS to a Friend at 6-months Postpartum. — 40 Participants